Teva Cites BG-12 Safety in Asking FDA to Add MS Reviews
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. asked U.S. regulators for more scrutiny before they approve any new multiple sclerosis drugs as it tries to block Biogen Idec Inc.’s BG-12 oral treatment from entering the market.
Teva, whose best-selling Copaxone injection controls about 40 percent of the MS market, requested that the U.S. Food and Drug Administration seek expert advice from the Peripheral and Central Nervous System Advisory Committee prior to clearing a treatment for the illness, according to a filing Dec. 31 on the U.S. government’s Citizen Petition website.